173 related articles for article (PubMed ID: 18493232)
1. Pegylated liposomal doxorubicin and gemcitabine in the front-line treatment of recurrent/metastatic breast cancer: a multicentre phase II study.
Adamo V; Lorusso V; Rossello R; Adamo B; Ferraro G; Lorusso D; Condemi G; Priolo D; Di Lullo L; Paglia A; Pisconti S; Scambia G; Ferrandina G
Br J Cancer; 2008 Jun; 98(12):1916-21. PubMed ID: 18493232
[TBL] [Abstract][Full Text] [Related]
2. Combination of pegylated liposomal doxorubicin plus gemcitabine in heavily pretreated metastatic breast cancer patients: Long-term results from a single institution experience.
Martin-Romano P; Baraibar I; Espinós J; Legaspi J; López-Picazo JM; Aramendía JM; Fernández OA; Santisteban M
Breast J; 2018 Jul; 24(4):473-479. PubMed ID: 29286192
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of pegylated liposomal doxorubicin (Caelyx) plus Gemcitabine in chemotherapeutically pretreated patients with advanced breast cancer.
Ulrich-Pur H; Kornek GV; Haider K; Kwasny W; Payrits T; Dworan N; Vormittag L; Depisch D; Lang F; Scheithauer W
Acta Oncol; 2007; 46(2):208-13. PubMed ID: 17453371
[TBL] [Abstract][Full Text] [Related]
4. Tolerability, efficacy, and safety of pegylated liposomal Doxorubicin in combination with Carboplatin versus gemcitabine-Carboplatin for the treatment of platinum-sensitive recurrent ovarian cancer: a systematic review.
Holloway RW; Grendys EC; Lefebvre P; Vekeman F; McMeekin S
Oncologist; 2010; 15(10):1073-82. PubMed ID: 20930103
[TBL] [Abstract][Full Text] [Related]
5. A randomized phase III study comparing pegylated liposomal doxorubicin with capecitabine as first-line chemotherapy in elderly patients with metastatic breast cancer: results of the OMEGA study of the Dutch Breast Cancer Research Group BOOG.
Smorenburg CH; de Groot SM; van Leeuwen-Stok AE; Hamaker ME; Wymenga AN; de Graaf H; de Jongh FE; Braun JJ; Los M; Maartense E; van Tinteren H; Nortier JWR; Seynaeve C
Ann Oncol; 2014 Mar; 25(3):599-605. PubMed ID: 24504445
[TBL] [Abstract][Full Text] [Related]
6. Pegylated liposomal doxorubicin and gemcitabine in a fixed dose rate infusion for the treatment of patients with poor prognosis of recurrent ovarian cancer: a phase Ib study.
Crespo G; Sierra M; Losa R; Berros JP; Villanueva N; Fra J; Fonseca PJ; Luque M; Fernández Y; Blay P; Sanmamed M; Muriel C; Esteban E; Lacave AJ
Int J Gynecol Cancer; 2011 Apr; 21(3):478-85. PubMed ID: 21436695
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of combination chemotherapy in early relapsed epithelial ovarian cancer using gemcitabine and pegylated liposomal doxorubicin.
Mirza MR; Lund B; Lindegaard JC; Keldsen N; Mellemgaard A; Christensen RD; Bertelsen K
Gynecol Oncol; 2010 Oct; 119(1):26-31. PubMed ID: 20638711
[TBL] [Abstract][Full Text] [Related]
8. Phase I/II study of gemcitabine with pegylated liposomal doxorubicin as first-line therapy in Asian women with metastatic breast cancer.
Wong ZW; Ang PC; Chowbay B; Wong NS; See HT; Khoo KS
Breast; 2008 Oct; 17(5):517-22. PubMed ID: 18502128
[TBL] [Abstract][Full Text] [Related]
9. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer.
Ferrandina G; Ludovisi M; Lorusso D; Pignata S; Breda E; Savarese A; Del Medico P; Scaltriti L; Katsaros D; Priolo D; Scambia G
J Clin Oncol; 2008 Feb; 26(6):890-6. PubMed ID: 18281662
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer.
Rivera E; Valero V; Arun B; Royce M; Adinin R; Hoelzer K; Walters R; Wade JL; Pusztai L; Hortobagyi GN
J Clin Oncol; 2003 Sep; 21(17):3249-54. PubMed ID: 12947059
[TBL] [Abstract][Full Text] [Related]
11. Gemcitabine and liposomal doxorubicin in the salvage treatment of ovarian cancer: updated results and long-term survival.
Ferrandina G; Paris I; Ludovisi M; D'Agostino G; Testa A; Lorusso D; Zanghi M; Pisconti S; Pezzella G; Adamo V; Breda E; Scambia G
Gynecol Oncol; 2005 Aug; 98(2):267-73. PubMed ID: 15975643
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of pegylated liposomal doxorubicin in combination with gemcitabine in metastatic breast cancer patients.
Jacquin JP; Chargari C; Thorin J; Mille D; Mélis A; Orfeuvre H; Clavreul G; Chaigneau L; Nourissat A; Dumanoir C; Savary J; Merrouche Y; Magné N
Am J Clin Oncol; 2012 Feb; 35(1):18-21. PubMed ID: 21278560
[TBL] [Abstract][Full Text] [Related]
13. Pegylated liposomal doxorubicin in combination with gemcitabine: a phase II study in anthracycline-naïve and anthracycline pretreated metastatic breast cancer patients.
Fabi A; Ferretti G; Papaldo P; Salesi N; Ciccarese M; Lorusso V; Carlini P; Carpino A; Mottolese M; Cianciulli AM; Giannarelli D; Sperduti I; Felici A; Cognetti F
Cancer Chemother Pharmacol; 2006 May; 57(5):615-23. PubMed ID: 16163541
[TBL] [Abstract][Full Text] [Related]
14. A pilot study evaluating the efficacy and toxicity of biweekly gemcitabine and pegylated liposomal doxorubicin in recurrent platinum-resistant epithelial ovarian cancer.
Tas F; Guney N; Derin D; Aydiner A; Topuz E
Int J Clin Oncol; 2008 Apr; 13(2):156-60. PubMed ID: 18463961
[TBL] [Abstract][Full Text] [Related]
15. Combined PEG liposomal doxorubicin and gemcitabine are active and have acceptable toxicity in patients with platinum-refractory and -resistant ovarian cancer after previous platinum-taxane therapy: a phase II Austrian AGO study.
Petru E; Angleitner-Boubenizek L; Reinthaller A; Deibl M; Zeimet AG; Volgger B; Stempfl A; Marth C
Gynecol Oncol; 2006 Aug; 102(2):226-9. PubMed ID: 16443259
[TBL] [Abstract][Full Text] [Related]
16. Gemcitabine plus doxorubicin as first-line treatment in advanced or metastatic breast cancer (MBC), a phase II study.
El Serafi MM; El Khodary AI; El Zawahry HR; Mansour OM; Gaballa HE
J Egypt Natl Canc Inst; 2006 Sep; 18(3):209-15. PubMed ID: 17671530
[TBL] [Abstract][Full Text] [Related]
17. Pegylated liposomal doxorubicin in combination with cyclophosphamide and trastuzumab in HER2-positive metastatic breast cancer patients: efficacy and cardiac safety from the GEICAM/2004-05 study.
Martín M; Sánchez-Rovira P; Muñoz M; Baena-Cañada JM; Mel JR; Margeli M; Ramos M; Martínez E; García-Saenz JA; Casado A; Jaén AM; González-Farré X; Escudero MJ; Rodriguez-Martin C; Carrasco E;
Ann Oncol; 2011 Dec; 22(12):2591-2596. PubMed ID: 21421542
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and toxicity of gemcitabine and pegylated liposomal Doxorubicin in recurrent platinum-resistant/refractory epithelial ovarian cancer.
Karaoglu A; Arslan UY; Ozkan M; Kalender ME; Alici S; Coskun U; Gumus M; Celenkoglu G; Er O; Sevinc A; Buyukberber S; Alkis N; Benekli M;
Asian Pac J Cancer Prev; 2009; 10(1):63-6. PubMed ID: 19469626
[TBL] [Abstract][Full Text] [Related]
19. Reduced incidence of severe palmar-plantar erythrodysesthesia and mucositis in a prospective multicenter phase II trial with pegylated liposomal doxorubicin at 40 mg/m2 every 4 weeks in previously treated patients with metastatic breast cancer.
Al-Batran SE; Meerpohl HG; von Minckwitz G; Atmaca A; Kleeberg U; Harbeck N; Lerbs W; Hecker D; Sehouli J; Knuth A; Jager E
Oncology; 2006; 70(2):141-6. PubMed ID: 16645327
[TBL] [Abstract][Full Text] [Related]
20. Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA).
Hamanishi J; Takeshima N; Katsumata N; Ushijima K; Kimura T; Takeuchi S; Matsumoto K; Ito K; Mandai M; Nakai H; Sakuragi N; Watari H; Takahashi N; Kato H; Hasegawa K; Yonemori K; Mizuno M; Takehara K; Niikura H; Sawasaki T; Nakao S; Saito T; Enomoto T; Nagase S; Suzuki N; Matsumoto T; Kondo E; Sonoda K; Aihara S; Aoki Y; Okamoto A; Takano H; Kobayashi H; Kato H; Terai Y; Takazawa A; Takahashi Y; Namba Y; Aoki D; Fujiwara K; Sugiyama T; Konishi I
J Clin Oncol; 2021 Nov; 39(33):3671-3681. PubMed ID: 34473544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
